IONS - Ionis Pharmaceuticals, Inc.
| Previous Close | 51.87 |
| Open | 52.49 |
| Bid | 51.84 x 1000 |
| Ask | 51.90 x 2900 |
| Day's Range | 51.43 - 52.67 |
| 52 Week Range | 39.07 - 59.81 |
| Volume | 214,121 |
| Avg. Volume | 1,089,009 |
| Market Cap | 7.143B |
| Beta (3Y Monthly) | 3.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.51 |
| Earnings Date | Feb 25, 2019 - Mar 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.46 |
Market Realist•4 days agoDo Analysts See Any Upside for Ionis Stock?
Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds,” and two have given it “sells.”
Market Realist•4 days agoUnderstanding Ionis Pharmaceuticals’ Operational Performance
In the most recent quarter, Ionis Pharmaceuticals’ (IONS) selling, general, and administrative expenses rose YoY (year-over-year) to $68.71 million from $26.79 million. Meanwhile, its R&D (research and development) expenses rose YoY to $95.25 million from $80.21 million due to higher drug development costs.
Market Realist•4 days agoTaking Stock of Ionis’s Performance
Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake. In its Core Ionis segment, the company is using its antisense technology to develop a pipeline of best-in-class drugs.
- Insider Monkey•4 days ago
Should You Buy Ionis Pharmaceuticals, Inc. (IONS)?
Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from industry insiders. They sometimes fail miserably but historically their consensus stock picks outperformed the market […]
Zacks•5 days agoThe Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
- Zacks•6 days ago
Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
A low key week for the biotech sector with focus on regular pipeline updates.
- Simply Wall St.•7 days ago
Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Expensive For A Reason? A Look At The Intrinsic Value
I am going to run you through how I calculated the intrinsic value of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by estimating the company's future cash flows and discounting them to their Read More...
Markit•12 days agoSee what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc NASDAQ/NGS:IONS
- GlobeNewswire•12 days ago
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
Biogen Inc (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) announced today that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1RX), an investigational treatment for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations. ALS with SOD1 mutations is a subtype of familial ALS and accounts for approximately two percent of all ALS cases.
- Investor's Business Daily•19 days ago
Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis
Dow Jones' component Pfizer will take the lion's share of the amyloidosis treatment market — leaving Alnylam and Ionis to duke it out for the remainder, an analyst says.
Markit•21 days agoSee what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
Short interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- PR Newswire•21 days ago
First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting
CARLSBAD, Calif., Nov. 27, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that data from the IONIS-TMPRSS6-LRx Phase 1 study, TEGSEDI™ (inotersen) and other Ionis research and development programs will be presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, December 1-4, 2018. The results to be reported at ASH demonstrate the potential for antisense therapeutics to address a broad range of diseases by potentially bringing transformational medicines to patients with severe diseases who have limited treatment options. IONIS-TMPRSS6-LRx, an antisense therapy in development for people suffering with beta-thalassemia and other potential indications, is one of several of Ionis' advanced LIgand Conjugated Antisense, or LICA, drugs to demonstrate potent target reduction and a favorable safety and tolerability profile in humans.
- Thomson Reuters StreetEvents•29 days ago
Edited Transcript of IONS earnings conference call or presentation 6-Nov-18 4:30pm GMT
Q3 2018 Ionis Pharmaceuticals Inc Earnings Call
- PR Newswire•last month
Ionis Pharmaceuticals to Present at Jefferies 2018 London Healthcare Conference
CARLSBAD, Calif., Nov. 13, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14 in London, United Kingdom. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective.
- InvestorPlace•last month
5 Pharma Stocks to Stay Away From
Pharma stocks can serve as a profitable addition to investment portfolios. With 10,000 baby boomers aging into Medicare every day, and a Medicare Part D drug plan to subsidize the cost, demographics and government subsidies has created a virtuous cycle for healthcare stocks. As a result, some have seen price levels that its profits (assuming they exist) cannot sustain. Additionally, biotech stocks are inherently risky due to the process of drug development and approval.
- Motley Fool•last month
Ionis Pharmaceuticals Collects Royalties -- and Spends It All
With $2 billion in the bank, the biotech can afford to invest in the future.
- GlobeNewswire•last month
Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced that data from the Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), were presented in a late-breaking clinical trial presentation at the American Heart Association Scientific Sessions in Chicago November 10, 2018. It is estimated that there are 8 to 10 million treatable patients living with cardiovascular disease and elevated levels of Lp(a).
- PR Newswire•last month
Ionis Pharmaceuticals to Host Investor Day
CARLSBAD, Calif., Nov. 9, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that management will host an Investor Day on Friday, December 7th at 7:30 a.m. Eastern Time at Marriott East Side in New York, NY. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.
- GlobeNewswire•last month
Recent Analysis Shows Automatic Data Processing, GTx, Ionis Pharmaceuticals, TriNet Group, Ternium S.A, and UNIVERSAL INSURANCE HOLDINGS INC Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Markit•last monthSee what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
Short interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
- GlobeNewswire•last month
Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced that clinical data on AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), will be presented at the American Heart Association Scientific Sessions in Chicago November 10-12, 2018. AKCEA-APO(a)-LRx is designed to inhibit production of apolipoprotein(a), or Apo(a) protein, thereby reducing systemic levels of lipoprotein(a), or Lp(a). It is estimated that there are 8 to 10 million treatable patients living with cardiovascular disease and elevated levels of Lp(a).
- PR Newswire•last month
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Nov. 7, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the ...
